The effect of altering heart rate on ventricular function in patients with heart failure treated with β-blockers

American Heart Journal

Volumn 152, Issue 4, 2006, Pages 713.e9-713.e13

  Thackray, Simon D R ^a   Ghosh, Justin M ^c   Wright, Graham A ^b   Witte, Klaus K A ^c   Nikitin, Nikolay P ^c   Kaye, Gerald C ^c   Clark, Andrew L ^c   Tweddel, Ann ^c   Cleland, John G F ^c  

^a UNIVERSITY OF HULL   (United Kingdom)

^b HULL ROYAL INFIRMARY   (United Kingdom)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARVEDILOL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; SPIRONOLACTONE;

AGED; ARTICLE; ARTIFICIAL HEART PACEMAKER; BRADYCARDIA; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FOLLOW UP; HEART FAILURE; HEART LEFT VENTRICLE CONTRACTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART PACING; HEART RATE; HEART VENTRICLE FUNCTION; HEART VOLUME; HUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RADIOISOTOPE VENTRICULOGRAPHY; RANDOMIZED CONTROLLED TRIAL;

EID: 33748711636     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2006.07.007     Document Type: Article

References (19)

1. Cleland J.G.F., Bristow M., Erdmann E., et al. Beta-blocking agents in heart failure: should they be used and how?. Eur Heart J 17 (1996) 1629-1639
2. Doughty R.N., Whalley G.A., Gamble G., et al. On behalf of the Australia and New-Zealand heart failure research collaborative group: left ventricular remodelling with carvedilol in patients with congestive heart failure due to ischaemic heart disease. JACC 29 (1997) 1060-1066
3. Dubach P., Myers J., Bonetti P., et al. Effects of bisoprolol fumarate on left ventricular size, function, and exercise capacity in patients with heart failure: analysis with magnetic resonance myocardial tagging. Am Heart J 143 (2002) 676-683
4. Bristow M.R., Ginsburg R., Minobe W., et al. Decreased catecholamine sensitivity and beta-adrenergic-receptor density in failing human hearts. N Engl J Med 307 (1982) 205-211
5. Lowes B.D., Gilbert E.M., Abraham W.T., et al. Myocardial gene expression in dilated cardiomyopathy treated with beta-blocking agents. N Engl J Med 346 (2002) 1357-1365
6. Poole-Wilson P.A., Swedberg K., Cleland J.G., et al. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial. Lancet 362 (2003) 7-13
7. Nagatsu M., Spinale F.G., Koide M., et al. Bradycardia and the role of β-blockade in the amelioration of left ventricular dysfunction. Circulation 101 (2000) 653-659
8. Cice G., Tagliamonte E., Ferrara L., et al. Efficacy of carvedilol on complex ventricular arrhythmias in dilated cardiomyopathy: double-blind, randomized, placebo-controlled study. Eur Heart J 21 (2000) 1259-1264
9. Cleland J.G., Pennell D.J., Ray S.G., et al. Carvedilol hibernating reversible ischaemia trial: marker of success investigators. Myocardial viability as a determinant of the ejection fraction response to carvedilol in patients with heart failure (CHRISTMAS trial): randomised controlled trial. Lancet 362 (2003) 14-21
10. Jourdain P., Funck F., Fulla Y., et al. Myocardial contractile reserve under low doses of dobutamine and improvement of left ventricular ejection fraction with treatment by carvedilol. Eur J Heart Fail 4 (2002) 269-276
11. Waagstein F., Swedberg K., Hjalmarson A., et al. Improvement after metoprolol in idiopathic dilated cardiomyopathy is predicted by baseline systolic blood pressure and change in heart rate. JACC 27 Suppl A (1996) 170A
12. Sackner-Bernstein J.D., Lukas M.A., and Wu B. Evidence against heart rate reduction as the primary mechanism of carvedilol in chronic heart failure. JACC 31 (1998) 32a
13. Lechat P., Hulot J.S., Escolano S., et al. Heart rate and cardiac rhythm relationships with bisoprolol benefit in chronic heart failure in CIBIS II Trial. Circulation 103 (2001) 1428-1433
14. Camm A.J., and Lau C.P. Electrophysiological effects of a single intravenous administration of ivabradine (s 16257) in adult patients with normal baseline electrophysiology. Drugs R D 4 (2003) 83-89
15. Thackray S.D., Witte K.K., Nikitin N.P., et al. The prevalence of heart failure and asymptomatic left ventricular systolic dysfunction in a typical regional pacemaker population. Eur Heart J 24 (2003) 1143-1152
16. Wright G.A., Thackray S., Howey S., et al. Left ventricular ejection fraction and volumes from gated blood-pool SPECT: comparison with planar gated blood-pool imaging and assessment of repeatability in patients with heart failure. J Nucl Med 44 (2003) 494-498
17. Cleland J.G., Ghosh J., Khan N.K., et al. Multi-chamber pacing: a perfect solution for cardiac mechanical dyssynchrony?. Eur Heart J 24 (2003) 384-390
18. Wilkoff B.L., Cook J.R., Epstein A.E., et al. Dual Chamber and VVI Implantable Defibrillator Trial Investigators Dual-chamber pacing or ventricular backup pacing in patients with an implantable defibrillator: the Dual Chamber and VVI Implantable Defibrillator (DAVID) Trial. JAMA 288 (2002) 3115-3123
19. Linde C., Leclercq C., Rex S., et al. Long-term benefits of biventricular pacing in congestive heart failure: results from the MUltisite STimulation in cardiomyopathy (MUSTIC) study. J Am Coll Cardiol 40 (2002) 111-118